Abstract
SARS-CoV-2 infection has significantly contributed to morbidity and mortality in patients with primary humoral immunodeficiencies, such as those with X-linked agammaglobulinemia (XLA) and common variable immunodeficiency (CVID). Currently, there is insufficient data to determine if mRNA vaccination and/or previous COVID-19 infection confers protection against rapidly mutating SARS-CoV-2 variants in patients with primary humoral immunodeficiencies. Evaluation of T-cell specific immune responses following vaccination against SARS-CoV-2 and omicron variant specific COVID-19 infection may help elucidate underlying mechanisms of protection for patients with primary humoral immunodeficiencies.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call